Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 9/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.39 |
| ▸ | PRKACG | P22612 | 3/20 | 0.39 |
| ▸ | PRKACB | P22694 | 3/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571926 | 1.00 | ROCK2 (0.57) | ROCK2ROCK1KITFLT3GRM5 | |
| SCHEMBL1572167 | 0.89 | ROCK2 (0.45) | ROCK2ROCK1KITFLT3PKN2 | |
| SCHEMBL1572165 | 0.89 | ROCK2 (0.45) | ROCK2ROCK1KITFLT3PKN2 | |
| SCHEMBL1571510 | 0.88 | ROCK2 (0.45) | ROCK2ROCK1KITFLT3PRKACA | |
| SCHEMBL1571509 | 0.88 | ROCK2 (0.45) | ROCK2ROCK1KITFLT3PRKACA | |
| SCHEMBL25834155 | 0.85 | KIT (0.52) | ROCK2ROCK1KITFLT3GRM5 | |
| SCHEMBL1571579 | 0.83 | ROCK1 (0.58) | ROCK2ROCK1KITFLT3PKN2 | |
| SCHEMBL1571580 | 0.83 | ROCK1 (0.58) | ROCK2ROCK1KITFLT3PKN2 | |
| SCHEMBL3319580 | 0.82 | ROCK2 (0.58) | ROCK2ROCK1PRKACAPRKACGPRKACB | |
| SCHEMBL1572362 | 0.81 | KIT (0.49) | ROCK2ROCK1KITFLT3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125744-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | SANOFI AVENTIS (FR) | 2011-04-13 | — | — | EP | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2125744-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077553-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056568-A1 | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | ROCK2 12/4885ROCK1 10/4885KIT 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.